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United Kingdom, and Sydney, AustraliaBackground: Live attenuated influenza vaccine (LAIV) is an
intranasal vaccine recently incorporated into the United
Kingdom immunization schedule. However, it contains egg
protein and, in the absence of safety data, is contraindicated in
patients with egg allergy. Furthermore, North American
guidelines recommend against its use in asthmatic children.
Objective: We sought to assess the safety of LAIV in children
with egg allergy.
Methods: We performed a prospective, multicenter, open-label,
phase IV intervention study involving 11 secondary/tertiary
centers in the United Kingdom. Children with egg allergy
(defined as a convincing clinical reaction to egg within the past
12 months and/or >95% likelihood of clinical egg allergy as per
published criteria) were recruited. LAIV was administered
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376Results: Four hundred thirty-three doses were administered to
282 children with egg allergy (median, 4.9 years; range, 2-17
years); 115 (41%) had experienced prior anaphylaxis to egg.
A physician’s diagnosis of asthma/recurrent wheezing was noted
in 67%, and 51% were receiving regular preventer therapy.
There were no systemic allergic reactions (upper 95% CI for
population, 1.3%). Eight children experienced mild self-limiting
symptoms, which might have been due an IgE-mediated allergic
reaction. Twenty-six (9.4%; 95% CI for population, 6.2% to
13.4%) children experienced lower respiratory tract symptoms
within 72 hours, including 13 with parent-reported wheeze.
None of these episodes required medical intervention beyond
routine treatment.
Conclusions: In contrast to current recommendations, LAIV
appears to be safe for use in children with egg allergy.
Furthermore, the vaccine appears to be well tolerated
in children with a diagnosis of asthma or recurrent wheeze. (J
Allergy Clin Immunol 2015;136:376-81.)
Key words: Egg allergy, live attenuated influenza vaccine, asthma,
recurrent wheezing, safety
Egg allergy is one of the most common food allergies in
childhood, with an estimated prevalence of at least 2% in
preschool children.1 Influenza vaccines generally contain egg
protein (including ovalbumin) because the vaccine virus is
cultured in hen’s eggs; only vaccines with an ovalbumin concen-
tration of less than 2 mg/mL are currently approved by the United
Kingdom (UK) national regulator. In theory, patients with egg al-
lergymight be at increased risk of an allergic reaction to influenza
vaccines. In recent years, inactivated influenza vaccines (IIVs)
with very low or no ovalbumin content have become available.
Observational studies have confirmed the safety of the parenteral
IIV in children with egg allergy, including those with a history of
previous anaphylaxis to egg,2,3 and have led to a relaxation of
contraindications relating to egg allergy in some guidelines.4-6
A trivalent live attenuated influenza vaccine (LAIV) adminis-
tered through the intranasal route has been available in the United
States for several years and received approval for use in Europe in
2010. The vaccine has high efficacy against influenza in children
aged 2 to 17 years,7,8 with a similar safety profile to IIVin children
without egg allergy.9-14 LAIV is also grown in hen’s eggs and con-
tains egg proteins. Until recently, there were no published data on
the safety of LAIV in children with egg allergy, and thus its use in
this population has been contraindicated.
Authorities in North America recommend annual influenza
vaccination in children from 2 to 8 years of age, preferably with
LAIV.6 LAIV is not licensed for use in children less than 2 years
of age because of an increased incidence of wheezing in this age
group after immunization.10,15 This effect has not been seen in
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wheeze,9 a finding confirmed in postmarketing surveillance
data.12,13 Nonetheless, current guidance from the US Centers
for Disease Control and Prevention recommends against using
LAIV in children less than 5 years of age with asthma or an
episode of wheezing in the previous year.6
In 2013, the UK introduced annual influenza immunization
using LAIV into the National Immunization Schedule for
children.17 Given that the rate of egg allergy in this age group is
estimated to be 2.5%, we estimate (on the basis of UK 2013 pop-
ulation data) that there are 60,000 children in this age group for
whom LAIV is contraindicated because of a diagnosis of egg
allergy. Therefore egg allergy is a significant barrier to successful
implementation of the immunization program, resulting in a
requirement to vaccinate children with egg allergy with IIV
administered by means of injection (typically in the hospital envi-
ronment), something which is less acceptable to families and
would incur significantly higher health costs. As a result, we
sought to assess the safety of LAIV in children with egg allergy
to provide data to inform an evidence-based consideration of a
change to current guidelines.METHODS
We conducted a phase IV open-label study of LAIV in children with egg
allergy during the UK influenza season (September 2013 to January 2014)
across 12 hospital-based allergy centers in the UK. Study participants were
recruited locally from allergy clinics. Eligible participants were aged 2 to 17
years with (1) IgE-mediated food allergy to egg, which was defined as a
positive food challenge result to egg within the last 12 months under medical
supervision; (2) a previous convincing clinical reaction to egg within the past
12 months with evidence of current sensitization on the basis of a positive skin
prick test response or serum-specific IgE level to egg white; or (3) evidence of
current sensitization consistent with a greater than 95% likelihood of clinical
egg allergy, as per published criteria.18 Patients with a history of prior anaphy-
laxis to egg or a history of severe but stable asthma were not excluded.
Anaphylaxis was defined by using World Allergy Organization criteria.19
Asthma was classified according to current therapy at the time of immuniza-
tion using the British Thoracic Society (BTS) and Scottish Intercollegiate
Guidelines Network (SIGN) guidelines.20 Skin prick testing was performed
in all participants before inclusion according to published guidelines to
confirm sensitization to egg (egg white extract; ALK-Abello, Hørsholm,
Denmark) and detect sensitization to potential aeroallergens. Testing and
vaccination were deferred if participants had received an antihistamine within
the previous 4 days. Participants were excluded if they had previously required
invasive ventilation for an anaphylactic reaction to egg, had severe unstable
asthma, or had a contraindication to LAIV, such as a prior allergic reaction
to a vaccine component (other than egg) or current salicylate therapy or had
experienced significant immunocompromise. Vaccinationwas deferred in par-
ticipants with acute febrile illness or evidence of increased asthma symptoms
for at least 2 weeks after symptom resolution.
The study was approved by theWestMidlands–Edgbaston Research Ethics
Committee (13/WM/0231), and the parent/guardian of each participant
provided written informed consent. Children older than 8 years wereencouraged to provide their own assent. The study sponsor was the University
Hospital Southampton NHS Foundation Trust (study no. RHM CHI0659).
This study was registered with ClinicalTrials.gov (NCT01859039) and the
European Union Clinical Trials Register (EudraCT 2013-002031-26).Procedures
Participants had baseline parameters (blood pressure, heart rate, respiratory
rate, and oxygen saturation)measured before LAIVadministration, with clinical
respiratory and dermatologic assessment at the same time. LAIV (Fluenz
[marketed as Flumist in North America] produced for the 2013-2014 influenza
season; AstraZeneca, London, UK) was administered into the nasal airway
according to the approved summary of product characteristics (ie, 0.1 mL per
nostril) in either the allergy day case or clinical research unit at each hospital site.
Participants were observed for at least 1 hour for symptoms of local or systemic
allergic reactions, as defined by international consensus.21 Clinical observations
were recorded for 60 minutes after vaccine administration, along with symptom
scoring (total ocular and nasal symptom score).22 In one center a subset of pa-
tients underwent acoustic rhinometry, an objective assessment of nasal airway
patency before and 10 minutes after LAIV administration, as previously
described.23 Emergency contact details were provided for parents to seek advice
in the event of any concerns after vaccination. Parents were contacted by tele-
phone after a minimum of 72 hours to detect any delayed adverse reaction.
Participants who had not received immunization with nonpandemic
influenza vaccine in previous years were offered a second dose of LAIV at
least 4 weeks later in line with the product recommendations.Outcomes
The primary outcome was the incidence of allergic reaction as an adverse
event after immunization occurring within 2 hours of LAIVadministration in
children with egg allergy. A systemic allergic reaction (anaphylaxis) was
defined according to the Brighton Collaboration case definition.24 Secondary
outcomes were as follows: incidence of delayed symptoms occurring up to 72
hours after LAIV administration; incidence of adverse events of nonallergic
cause after LAIV administration; and change in nasal airway patency in
children who underwent acoustic rhinometry as an additional assessment.
The causality of all adverse events was confirmed by an independent data
monitoring committee in conjunction with the local study team.Statistical analyses
Analyses were planned prospectively and detailed in a statistical analysis
plan. The incidence of reactions to LAIV (both immediate and delayed) was
estimated with 2-sided exact 95% CIs. For subgroup analyses, incidences of
reactions were compared between different cohorts by using a 2-sided Fisher
exact test. Sample size was considered with respect to a historical comparison
and also based on the precision around an estimate of zero. If there were no
allergic reactions in a sample size of 300, then this would provide confidence
(based on the upper end of the 2-sided 95% CI) that the true rate of allergic
reaction to LAIV in children with egg allergy within the population is no more
than 1.2%. The analysis data set was as treated and with relevant safety data
measured.RESULTS
Two hundred eighty-two children with egg allergy were
enrolled in the study and received at least 1 dose of LAIV
between September 2013 and January 2014. The median age of
the cohort was 4.9 years (range, 2-17 years; interquartile range
[IQR], 3-8 years), and 185 (66%) were male. A total of 433 doses
of LAIV were administered to 282 children, 64 with prior
influenza vaccination and 218 vaccine-naive children, as
depicted in Fig 1. One hundred fifty-one children received a sec-
ond dose of LAIV 4 weeks later. The reasons for only a single
dose of LAIV being administered in the remainder are shown in
FIG 1. Patient flow diagram. *One child could not receive LAIV because a family member had commenced
immunosuppressant therapy for medical reasons. This child was given IIV instead.
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dose because of unavailability of in-date vaccine; none of these
children were in a high-risk clinical category requiring 2 doses ac-
cording to UK immunization guidelines.17
All children had evidence of current egg allergy at the time of
immunization. One hundred forty-five (51%) children experi-
enced an allergic reaction to egg in the last 12 months with
evidence of sensitization at enrollment. Twenty-two (8%) had
undergone formal, in-hospital food challenges to egg within the
previous 12 months to substantiate their diagnosis. A total of 137
(49%) had not reacted to egg in the last 12 months but had
evidence of sensitization (ie, greater than the published criteria of
>95% positive predictive values for clinical egg allergy).20 Only
35 (12%) had never eaten egg and were given a diagnosis based
on results of predictive allergy testing alone. The median
skin prick test response to egg white was 7 mm (IQR, 5-9 mm;
range, 0-16 mm), and the median serum-specific IgE level was12.1 kUA/L (IQR, 2.9-35.2 kUA/L; range, 0->100 kUA/L). The
cohort included 115 (41%) children with a history of prior
anaphylaxis to egg, of whom 68 (24%) had experienced
respiratory symptoms, cardiovascular symptoms, or both with
egg ingestion. Seventy-six (27%) were currently tolerating baked
egg (eg, in cakes) at the time of enrollment.Physician-diagnosed asthma/recurrent wheeze
One hundred eighty-eight (67%) children had a physician’s
diagnosis of asthma or recurrent wheeze, of whom 145 (51% of
total cohort) were using daily preventer therapy (BTS/SIGN step
2 or greater). Sixty-nine (25%) were using high-dose inhaled
corticosteroids, multiple preventer therapy, or both. One
hundred fifty-seven (56%) had allergic rhinitis, 180 (64%) had
atopic eczema, and 138 (49%) were allergic to 3 or more food
groups.
TABLE I. Delayed adverse events reported by parents
Delayed symptoms
experienced after LAIV
No. of
doses
No. of
children
Rate in
cohort
95% CI
for population
Denominator (no. of
doses/children in study)
426 278
Upper respiratory
Upper respiratory (any) 65 59 21.2% 16.6% to 26.5%
Isolated symptoms only,
<24-h duration
23 22 7.9% 5.0% to 11.7%
Isolated symptoms only,
>24-h duration
9 9 3.2% 1.5% to 6.1%
Nasal symptoms with
ocular involvement
6 6 2.2% 0.8% to 4.6%
Lower respiratory
Lower respiratory (any) 26 26 9.4% 6.2% to 13.4%
Parent-reported wheeze 13 13 4.7% 2.5% to 7.9%
Constitutional
Any 31 31 11.2% 7.7% to 15.5%
Fever <24 h 20 20 7.2% 4.4% to 10.9%
Fever >24 h 5 3 1.1% 0.2% to 3.1%
Other: lethargy, headache,
dizziness, myalgia
8 8 2.9% 1.3% to 5.6%
Dermatological
Flare in eczema 13 11 4.0% 2.0% to 7.0%
Nonspecific rash, no
response to
antihistamine
2 2 0.7% 0.1% to 2.6%
Abdominal symptoms
Vomiting, nausea,
abdominal pain
11 11 4.0% 2.0% to 7.0%
Loose stools 6 6 2.2% 0.8% to 4.6%
Ear-nose-throat
Mild epistaxis 1 1 0.4% 0.01% to 4.6%
Ocular
Itch, redness 8 8 2.9% 1.3% to 5.6%
Neurological
Any 0 0 0% 0% to 1.3%
Cardiovascular
Any 0 0 0% 0% to 1.3%
TABLE II. Rates of adverse events occurring within 72 hours
after LAIV administration in this study compared with pub-
lished rates in the literature
Symptoms within 72 h Current study Reported
Allergic reaction (mild symptoms) only 9/433 2.1% 0.02%
Allergic reaction: anaphylaxis 0/433 0% 0%
Fever 25/426 5.9% 5.4%
Nasal symptoms 65/426 15.3% 31%
Wheeze (parent reported) 13/426 3.1% Not reported
Wheeze requiring treatment by physician 0/426 0% 0.2%
Lower respiratory symptoms 26/426 6.1% Not reported
Eczema flare 13/426 3.1% Not reported
Rates are reported as a proportion of the total number of doses given to be consistent
with the method of reporting used in the existing literature.10
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There were no systemic reactions in the cohort of 282 children.
On the basis of these data, the 95% upper CI for the incidence of a
systemic allergic reaction (including anaphylaxis) to LAIV in
children with egg allergy was 1.3%. The median baseline total
ocular and nasal symptom score was 0 (IQR, 0-1); this did
not increase at 10, 30, or 60 minutes after LAIV administration
(P > .05, Wilcoxon signed-rank test).
A total of 14 adverse events in 14 different children were
reported within 2 hours of vaccine administration (3.2% of all
doses given), 8 of which were consistent with a potential
IgE-mediated allergic response, as defined by international
consensus.19 Thus 2.8% of participants experienced an immediate
adverse event after immunization of possible allergic cause.
These reactions (6 episodes of rhinitis, 1 episode of localized
urticaria, and 1 episode of mild gastrointestinal discomfort)
were mild and self-limiting and occurred within 30 minutes of
LAIV administration. The remaining events were as follows: 1
episode of fever; 1 child who had a mild flare in eczema 45
minutes after LAIV administration; 2 episodes of nasal obstruc-
tion alone without concurrent symptoms of nasal itch/sneezing;
and 2 children who had transient, localized, nonspecific skinsymptoms (itchy chin without skin signs; 3 nonitchy papules
above the upper lip) in the absence of any features to suggest an
allergic reaction. All but 1 of these events occurred with the first
dose of LAIV. Three of these children received a second dose of
LAIV 4 weeks later without reaction.
No risk factors were identified for occurrence of an acute
adverse event, allergic or otherwise, when assessed for age,
severity of egg allergy, previous influenza vaccination,
tolerance to baked egg, and presence of physician-diagnosed
asthma/recurrent wheezing or allergic rhinitis (P >.05 for all com-
parisons, Fisher exact test).
Acoustic rhinometry was performed in 13 children: no
significant change in minimal cross-sectional area of the nasal
airway (suggestive of nasal congestion) was observed
(median change in nasal patency, 25.3%; IQR, 218.7% to
18.6%; P 5 .97, Wilcoxon signed-rank test). None of these chil-
dren reported nasal symptoms.Delayed adverse events after immunization
After excluding events in 7 patients that were deemed unrelated
or unlikely to be related to vaccination by the independent data
monitoring committee, 73 (of 278) children had delayed events
(occurring between 2 and 72 hours after vaccine administration)
reported after the first dose, and 35 (of 148) had delayed events
after the second dose. Across both doses, 91 children had a
delayed event after at least 1 dose of LAIV. The delayed events are
summarized in Table I. Twenty-six (9.4%; 95%CI for population,
6.2% to 13.4%) children experienced lower respiratory tract
symptoms within 72 hours, including 13 (4.7%; 95% CI for pop-
ulation, 2,5% to 7.9%) children with parent-reported wheeze.
Children with a diagnosis of recurrent wheeze or asthma were
not more likely to experience any adverse events than those
without (59/186 [32%] vs 32/92 [35%], respectively; P 5 .68)
or wheeze/cough (18/186 [10%] vs 8/92 [9%], P 5 1.00) after
LAIV administration. Wheeze/cough was not more common in
children receiving regular inhaled corticosteroid (BTS/SIGN
step 2 therapy or greater, P5 .55). Medical review by the child’s
primary care physician was sought in 2 cases, but no change in
medication or treatment resulted. No child presented to the hospi-
tal because of a reported adverse event within 72 hours. No
serious adverse events reported during the study were attributable
to LAIV administration.
In the 148 children who received 2 doses of LAIVand in whom
follow-up was complete, 20 (13.5%) were reported to have
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for both doses. In only 4 cases were symptoms similar in both
reactions, and in 2 of 4 cases the reported adverse event after
immunization was an eczema flare.DISCUSSION
In this highly atopic cohort of children with egg allergy, there
were no systemic allergic reactions or episodes of anaphylaxis
after administration of LAIV. This equates to an upper 95% CI of
1.3% for the incidence of an acute systemic allergic reaction for
children with egg allergy in the population. Des Roches et al25
recently reported a cohort of 68 children with a diagnosis of
egg allergy who received LAIVwithout an allergic reaction; how-
ever, the criteria used to define egg allergy in their cohort were
less stringent than in the current study, and thus a proportion of
the children reported in that studymight have no longer been clin-
ically allergic to egg.
The rate observed for attributable allergic reactions after
vaccine (2.8%) is higher than previously reported.10 These reac-
tions were all mild, localized, and self-limiting. Safety data
from postmarketing surveillance in the United States has shown
LAIV to be awell-tolerated vaccine.12-14,26 Baxter et al14 reported
9 episodes of urticaria occurring within 3 days of LAIVadminis-
tration in children aged 5 to 17 years of 43,702 doses administered
during the period 2003-2008. However, it is unclear how many of
these episodes occurred within 2 hours of LAIV administration,
which is consistent with an IgE-mediated mechanism caused by
LAIV. In a further surveillance study of 2.5 million doses of
LAIV in adults, 7 cases of systemic allergic reactions (anaphy-
laxis) occurred, which is equivalent to a rate of 0.3 reactions
per 100,000 doses; none were related to egg allergy, and only 5
were deemed to be causally related to LAIV administration.27
A randomized, double-blind, placebo-controlled trial of the
safety of LAIV in children aged 6 to 59 months without egg
allergy reported that the most common adverse event was
rhinorrhea/nasal congestion.10 This has been subsequently
confirmed in postmarketing surveillance studies.27 Despite the
high rate of atopy in our cohort, the rates of adverse events
were similar to those previously reported (Table II).10 In this study
children with asthma (including those using preventer therapy) or
recurrent wheeze were not at greater risk of parent-reported
wheeze in the 72 hours after LAIV administration. It was not
possible to compare rates of wheezewith those of previous studies
because the latter refer to ‘‘medically significant wheeze’’ diag-
nosed by a health care professional occurring up to 42 days after
vaccine administration; unfortunately, rates of parent-reported
lower respiratory tract symptoms in the days after LAIV have
not been assessed in prior studies. Furthermore, children
requiring higher levels of asthma treatment (BTS step 3 or
greater) were not at higher risk of parent-reported wheeze, a
group that still constituted 25% of our cohort.
A report of 2 randomized multinational trials comparing LAIV
with IIV in 1940 children aged 2 to 5 years with asthma or a
history of wheezing found no difference between the incidence of
wheezing after vaccination between those who received LAIV
and IIV.8 The rates of lower respiratory tract symptoms ranged
from 5% to 29.9% (any wheeze within 42 days of vaccine
administration) and are similar to our study. Other studies in older
children have likewise found no evidence for an increase inasthma exacerbation or medically significant wheeze after
LAIV compared with IIV.9,16 It is clear that wheeze is a relatively
common symptom in this group of children. In contrast to UK
guidance, guidelines in the Unites States and Canada currently
recommend against the use of LAIV in children with asthma,
although this advice was recently been revised, permitting the
use of LAIV in children aged 2 to 4 years without symptoms of
wheezing in the 12 months before vaccination.6 We found no
evidence for an increase in ‘‘medically significant wheezing’’ af-
ter LAIV in those children with a history of recurrent wheeze or
asthma. We are unable to determine whether the episodes of
wheezing observed would have occurred in the absence of
LAIV immunization.
Analysis of the 4 batches of LAIVused during this study for the
Department of Health, England, found the maximum concentra-
tion of ovalbumin present to be less than 0.3 ng/mL. However, the
egg protein content of influenza vaccine varies between batches,
and our data might not be applicable to future stocks of LAIV in
which the egg content of the vaccine might be higher.28,29 The
maximum level of ovalbumin permitted in LAIVunder the license
granted by the European Medicines Agency is 1.2 mg/mL30; this
is approximately 10 times lower than the amount of egg protein
found to trigger local rhinitis symptoms when administered into
the nasal airways of children with egg allergy.31 Therefore it is un-
likely that LAIV would be expected to trigger symptoms because
of an IgE-mediated allergic reaction to egg.
In summary, these data have demonstrated a safety profile in
terms of systemic allergic reactions to LAIV (supplied during the
2013-2014 influenza season) in children with egg allergy,
including those with a prior history of anaphylaxis, similar to
that previously reported for children without egg allergy.
Furthermore, the vaccine appears to be well tolerated in children
with a diagnosis of asthma or recurrent wheeze.
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